galantamine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boada, M; Carnero-Pardo, C; Fortea, J; García-Ribas, G; Martínez-Lage, P; Olazarán, J; Sánchez-Juan, P; Viñuela, F | 1 |
| Ahmad, F | 1 |
2 other study(ies) available for galantamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Pandemics; Phenylcarbamates; Piperidines; Prevalence; Retrospective Studies; Rivastigmine | 2023 |
COVID-19 induced ARDS, and the use of galantamine to activate the cholinergic anti-inflammatory pathway.
Topics: Arthritis, Rheumatoid; Cholinesterase Inhibitors; COVID-19; Galantamine; Humans; Neuroimmunomodulation; Pandemics; Respiratory Distress Syndrome; SARS-CoV-2; Vagus Nerve Stimulation | 2020 |